Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nevanac vs Acular LS for Ocular Inflammation in Cataract Surgery
NCT00333255Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Sep 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nepafenac in ocular inflammation (2 arms), sponsored by Alcon Inc. Primary endpoint: Percentage of patients who are a clinical success at Day 14. Started Sep 2005; status: completed.
02
Drugs
nepafenac
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT00333255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333255.